Tech Company Financing Transactions
ITM Isotope Technologies Funding Round
Temasek, Athos Capital and BlackRock participated in a $201 million capital raise for ITM Isotope Technologies. The funding round was announced on 6/6/2024.
Transaction Overview
Company Name
Announced On
6/6/2024
Transaction Type
Venture Equity
Amount
$201,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to advance and expand its radiopharmaceutical pipeline, foster its development platform and prepare commercial readiness for the potential market launch of its phase III lead candidate, ITM-11 (n.c.a. 177Lu-edotreotide) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Funds will also enable expansion of manufacturing capabilities for the production of alpha- and beta-emitting radioisotopes, including Lutetium-177(177Lu) and Actinium-225(225Ac).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Walther-von-Dyck-Strasse 4
Garching / Munich, 85748
Germany
Garching / Munich, 85748
Germany
Phone
Website
Email Address
Overview
ITM Isotope Technologies Munich SE is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 6/6/2024: PPC.io venture capital transaction
Next: 6/6/2024: Eyebot venture capital transaction
Share this article
About Our VC Transactions Data
We report on funding rounds that are announced publicly. VC investment data records reported here are derived from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs